Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.01 USD
-0.02 (-1.94%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $1.00 -0.01 (-0.99%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Galena Biopharma, Inc. (SLS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.50 | $9.00 | $4.00 | 531.07% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Galena Biopharma, Inc. comes to $6.50. The forecasts range from a low of $4.00 to a high of $9.00. The average price target represents an increase of 531.07% from the last closing price of $1.03.
Analyst Price Targets (2 )
Broker Rating
Galena Biopharma, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
2/2/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $6.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 252 |
Current Quarter EPS Est: | NA |